The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Subscribe To Our Newsletter & Stay Updated
